Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 2
1983 2
1984 3
1985 1
1986 2
1987 4
1988 4
1990 3
1991 1
1992 6
1993 9
1994 13
1995 9
1996 13
1997 4
1998 8
1999 13
2000 9
2001 12
2002 15
2003 12
2004 7
2005 16
2006 14
2007 8
2008 10
2009 9
2010 8
2011 20
2012 20
2013 25
2014 15
2015 10
2016 16
2017 18
2018 20
2019 13
2020 10
2021 15
2022 24
2023 13
2024 18
2025 24
2026 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

454 results

Results by year

Filters applied: . Clear all
Page 1
Current Pharmacological Treatments for ADHD.
Groom MJ, Cortese S. Groom MJ, et al. Curr Top Behav Neurosci. 2022;57:19-50. doi: 10.1007/7854_2022_330. Curr Top Behav Neurosci. 2022. PMID: 35507282 Review.
Attention-Deficit Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental condition associated with impaired function and increased risk of poor outcomes in children, young people and adults with the condition. Currently approved pharmac …
Attention-Deficit Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental condition associated wi …
Evidence-based pharmacological treatment options for ADHD in children and adolescents.
Mechler K, Banaschewski T, Hohmann S, Häge A. Mechler K, et al. Pharmacol Ther. 2022 Feb;230:107940. doi: 10.1016/j.pharmthera.2021.107940. Epub 2021 Jun 23. Pharmacol Ther. 2022. PMID: 34174276 Free article. Review.
Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity, causing functional impairment. ...Available medications include stimulants (methylphenid …
Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by …
Nonstimulant Treatments for ADHD.
Newcorn JH, Krone B, Dittmann RW. Newcorn JH, et al. Child Adolesc Psychiatr Clin N Am. 2022 Jul;31(3):417-435. doi: 10.1016/j.chc.2022.03.005. Epub 2022 May 11. Child Adolesc Psychiatr Clin N Am. 2022. PMID: 35697393 Review.
Here, we discuss monotherapy and combined treatment of ADHD and review mechanism of action, pharmacokinetics, efficacy, tolerability, and safety of approved, off-label, and pipeline nonstimulants. ...Availability of nonstimulant medications enhances our opportunity to offe …
Here, we discuss monotherapy and combined treatment of ADHD and review mechanism of action, pharmacokinetics, efficacy, tolerability, …
A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD).
Sharma A, Couture J. Sharma A, et al. Ann Pharmacother. 2014 Feb;48(2):209-25. doi: 10.1177/1060028013510699. Epub 2013 Nov 1. Ann Pharmacother. 2014. PMID: 24259638 Review.
OBJECTIVE: To review the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). DATA SOURCES AND DATA EXTRACTION: A literature search was conducted in PubMed and EMBASE using the terms attention de …
OBJECTIVE: To review the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder ( …
Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A. Cortese S, et al. Lancet Psychiatry. 2018 Sep;5(9):727-738. doi: 10.1016/S2215-0366(18)30269-4. Epub 2018 Aug 7. Lancet Psychiatry. 2018. PMID: 30097390 Free PMC article.
BACKGROUND: The benefits and safety of medications for attention-deficit hyperactivity disorder (ADHD) remain controversial, and guidelines are inconsistent on which medications are preferred across different age groups. We aimed to estimate the …
BACKGROUND: The benefits and safety of medications for attention-deficit hyperactivity disorder (ADHD) re …
In utero exposure to ADHD medication and long-term offspring outcomes.
Bang Madsen K, Robakis TK, Liu X, Momen N, Larsson H, Dreier JW, Kildegaard H, Groth JB, Newcorn JH, Hove Thomsen P, Munk-Olsen T, Bergink V. Bang Madsen K, et al. Mol Psychiatry. 2023 Apr;28(4):1739-1746. doi: 10.1038/s41380-023-01992-6. Epub 2023 Feb 9. Mol Psychiatry. 2023. PMID: 36759544
Attention Deficit Hyperactivity Disorder (ADHD) medication is increasingly being used during pregnancy. ...Neurodevelopment and growth in offspring do not differ based on antenatal exposure to ADHD medication. These findings provide reass …
Attention Deficit Hyperactivity Disorder (ADHD) medication is increasingly being used during pregnancy. . …
Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis.
Radonjić NV, Bellato A, Khoury NM, Cortese S, Faraone SV. Radonjić NV, et al. CNS Drugs. 2023 May;37(5):381-397. doi: 10.1007/s40263-023-01005-8. Epub 2023 May 11. CNS Drugs. 2023. PMID: 37166701
BACKGROUND: For some adults with Attention-Deficit/Hyperactivity Disorder (ADHD), nonstimulants need to be considered either as a monotherapy or as an adjunct to stimulants. ...CONCLUSIONS: All investigated nonstimulants were more efficac …
BACKGROUND: For some adults with Attention-Deficit/Hyperactivity Disorder (ADHD), nonstimulants ne …
Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
Osland ST, Steeves TD, Pringsheim T. Osland ST, et al. Cochrane Database Syst Rev. 2018 Jun 26;6(6):CD007990. doi: 10.1002/14651858.CD007990.pub3. Cochrane Database Syst Rev. 2018. PMID: 29944175 Free PMC article.
BACKGROUND: This is an update of the original Cochrane Review published in Issue 4, 2011.Attention deficit hyperactivity disorder (ADHD) is the most prevalent of the comorbid psychiatric disorders that complicate tic disorders. ...Alpha agonists …
BACKGROUND: This is an update of the original Cochrane Review published in Issue 4, 2011.Attention deficit hyperactivity …
Clonidine oral suspension (Onyda XR) for ADHD.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2024 Dec 23;66(1718):205-206. doi: 10.58347/tml.2024.1718d. Med Lett Drugs Ther. 2024. PMID: 39762190 No abstract available.
European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment.
Roessner V, Eichele H, Stern JS, Skov L, Rizzo R, Debes NM, Nagy P, Cavanna AE, Termine C, Ganos C, Münchau A, Szejko N, Cath D, Müller-Vahl KR, Verdellen C, Hartmann A, Rothenberger A, Hoekstra PJ, Plessen KJ. Roessner V, et al. Eur Child Adolesc Psychiatry. 2022 Mar;31(3):425-441. doi: 10.1007/s00787-021-01899-z. Epub 2021 Nov 10. Eur Child Adolesc Psychiatry. 2022. PMID: 34757514 Free PMC article. Review.
We now present an update of the part on pharmacological treatment, based on a review of new literature with special attention to other evidence-based guidelines, meta-analyses, and randomized double-blinded studies. ...Other agents that can be considered include tiapride, …
We now present an update of the part on pharmacological treatment, based on a review of new literature with special attention to othe …
454 results